Please type a plus sign (+) inside this box →

DT15 d PCT/PTO 02 MAR 2005

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	~~Unassigned~~ 10/526851
Filing Date	~~Herewith~~
First Named Inventor	Kozikowski et al.
Group Art Unit	~~Unassigned~~ 1626
Examiner Name	~~Unassigned~~ Jason Nolan
Attorney Docket Number	234590

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document: Application or Patent Number	U.S. Patent Document: Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
JN	AA	5,227,508		Kozikowski et al.	Jul. 13, 1993	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Doc. No.	Foreign Patent Document: Office	Foreign Patent Document: Application or Patent Number	Foreign Patent Document: Kind Code	Name of Patentee or Applicant	Date of Publication	Translation: Yes	Translation: No**
JN	AB	WO	00/00206	A1	Georgetown University	Jan. 6, 2000		

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation: Yes	Translation: No**
~~JN~~	~~AC~~	~~HU et al., *Tetrahedron Letters*, 41, 7415-7418 (2000)~~ IN other IDS		
JN	AD	QIAO et al., *J. Med. Chem.*, *41(18)*, 3303-3306 (1998)		

Examiner Signature	/Jason Nolan/	Date Considered	01/31/2007

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

\+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → +

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known	
Application Number	10/526,851
Filing Date	May 19, 2005
First Named Inventor	Kozikowski, et al.
Group Art Unit	1626
Examiner Name	Nolan, Jason Michael
Attorney Docket Number	234590
Client Reference No.	KOAL426532

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document: Application or Patent Number	U.S. Patent Document: Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Doc. No.	Foreign Patent Document: Office	Foreign Patent Document: Application or Patent Number	Foreign Patent Document: Kind Code	Name of Patentee or Applicant	Date of Publication	Translation: Yes	Translation: No*+

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation: Yes	Translation: No*+
JN	AE	BALENDRAN et al., PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2, *Curr Biol., 9,* 393-404 (1999)		
	AF	BELLACOSA et al., P. N. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region, *Science, 254,* 274-277 (1991)		
	AG	BLAIR et al., Akt-dependent potentiation of L channels by insulin-like growth factor- 1 is required for neuronal survival, *J Neurosci, 19,* 1940-1951 (1999)		
	AH	BROGNARD et al., Akt/protein kinase b is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation, *Cancer Res., 61,* 3986-3997 (2001)		
	AI	BRUNET et al., Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor, *Cell, 96,* 857-868 (1999)		
	AJ	CARDONE et al., Regulation of cell death protease caspase-9 by phosphorylation, *Science, 282,* 1318-1321 (1998)		
	AK	CHALECKA-FRANASZEK et al., Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons, *Proc Natl Acad Sci U S A, 96,* 8745-8750 (1999)		
	AL	CHEN et al., Suppression of transforming growth factor-β-induced apoptosis through a phosphatidylinositol 3-kinase/Akt-dependent pathway, *Oncogene, 17,* 1959-1968 (1998)		
	AM	CLARK et al., Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, and tamoxifen in breast cancer cells, *Molec Canc Ther., 1,* 707-717 (2002)		
	AN	COFFER et al., Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families, *Eur J Biochem., 201,* 475-481 (1991)		
	AO	CROWDER et al., Phosphatidylinositol 3-kinase and Akt protein kinase are necessary and sufficient for the survival of nerve growth factor-dependent sympathetic neurons. *J Neurosci, 18,* 2933-2943 (1998)		
	AP	DATTA et al., Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery, *Cell, 91,* 231-241 (1997)		
	AQ	DATTA et al., Cellular survival: a play in three Akts, *Genes Dev., 13,* 2905-2927 (1999)		

Examiner Signature	/Jason Nolan/	Date Considered	01/31/2007

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

\+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → +

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 3

Complete if Known	
Application Number	10/526,851
Filing Date	May 19, 2005
First Named Inventor	Kozikowski, et al.
Group Art Unit	1626
Examiner Name	Nolan, Jason Michael
Attorney Docket Number	234590
Client Reference No.	KOAL426532

OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation Yes	Translation No*+
JN	AR	DEL PESO et al., Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt, *Science, 278,* 687-689 (1997)		
	AS	DELCOMMENNE et al., Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase, *Proc Natl Acad Sci U S A, 95,* 11211-11216 (1998)		
	AT	DUDEK et al., Regulation of Neuronal Survival by the Serine-Threonine Protein Kinase Akt, *Science, 275,* 661-665 (1997)		
	AU	EVES et al., N. Akt, a target of phosphatidylinositol 3-kinase, inhibits apoptosis in a differentiating neuronal cell line, *Mol Cell Biol., 18,* 2143-2152 (1998)		
	AV	FILIPPA et al., Mechanism of protein kinase B activation by cyclic AMP-dependent protein kinase, *Mol Cell Biol., 19,* 4989-5000 (1999)		
	AW	GERBER et al., Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway, *J Biol Chem., 273,* 30336-30343 (1998)		
	AX	HAUSLER et al., Protection of CD95-mediated apoptosis by activation of phosphatidylinositide 3-kinase and protein kinase B, Eur *J Immunol, 28,* 57-69 (1998)		
	AY	HU et al., Synthesis and AKT inhibitory properties of a 1D-3, 4-dideoxyphosphatidylinositol ether lipid, *Tetrahedron Letters, 41,* 7415-7418 (2000)		
	AZ	JONES et al., Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily, *Proc Natl Acad Sci U S A, 88,* 4171-4175 (1991)		
	BA	KANG et al., Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit, *J Biol Chem., 274,* 13085-13090 (1999)		
	BB	KAUFFMANN-ZEH et al., Suppresion of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB, *Nature, 385,* 544-548 (1997)		
	BC	KENNEDY et al., Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome *c* from mitochondria, *Mol Cell Biol., 19,* 5800-5810 (1999)		
	BD	KHWAJA et al., Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway, *The EMBO Journal, 16,* 2783-2793 (1997)		
	BE	KOPS et al., Direct control of the Forkhead transcription factor AFX by protein kinase B, *Nature, 398,* 630-634 (1999)		
	BF	KOZIKOWSKI et al., Synthesis of 1D-3-Deoxy-and-2, 3-Dideoxyphosphatidylinositol., *Tetrahedron, 53,* 14903-14914 (1997)		
	BG	KULIK et al., Antiapoptotic Signalling by the Insulin-Like Growth Factor I Receptor, Phosphatidylinositol 3-Kinase, and Akt, *Molecular and Cellular Biology, 17,* 1595-1606 (1997)		
	BH	KULIK et al., Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I, *Molecular and Cellular Biology, 18,* 6711-6718 (1998)		
	BI	LYNCH et al., Integrin-linked kinase regulates phosphorylation of serine 473 of protein kinase B by an indirect mechanism, *Oncogene, 18:* 8024-8032 (1999)		

Examiner Signature	/Jason Nolan/	Date Considered	01/31/2007

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

\+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 3

Complete if Known	
Application Number	10/526,851
Filing Date	May 19, 2005
First Named Inventor	Kozikowski, et al.
Group Art Unit	1626
Examiner Name	Nolan, Jason Michael
Attorney Docket Number	234590
Client Reference No.	KOAL426532

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation Yes	Translation No*+
JN	BJ	OZES et al., NF-κB activation by tumour necrosis factor requires the Akt serine- threonine kinase, *Nature, 401,* 82-85 (1999)		
	BK	QIAO et al., A Versatile Approach to PI(3,4) P_2, PI(4,5)P_2, and PI(3,4,5)P_3 from L-(-)-Quebrachitol, *Organic Letters, 2,* 115-117 (2000); Published on Web 12/22/1999		
	BL	ROHN et al., The opposing roles of the Akt and c-Myc signalling pathways in survival from CD95-mediated apoptosis, *Oncogene, 17,* 2811-2818 (1998)		
	BM	ROMASHKOVA et al., NF-κB is a target of AKT in anti-apoptotic PDGF signaling, *Nature, 401,* 86-90 (1999)		
	BN	RUST et al., The bile acid taurochenodeoxycholate activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade, *J Biol Chem., 275,* 20210-20216 (2000)		
	BO	TESTA et al., AKT plays a central role in tumorigenesis, *Proc Natl Acad Sci U S A, 98,* 10983-10985 (2001)		
	BP	TOKER et al., Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site, *J Biol Chem., 275,* 8271-8274 (2000)		
	BQ	YANO et al., Calcium promotes cell survival through CaM-K kinase activation of the protein-kinase-B pathway, *Nature, 396,* 584-587 (1998)		

Examiner Signature	/Jason Nolan/	Date Considered	01/31/2007

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

\+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).